Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma

Journal of Oncology

Volumn , Issue , 2012, Pages

  Du, Li ^a,b   Shen, Jingping ^a   Weems, Andrew ^c   Lu, Shi Long ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; BIOLOGICAL MARKER; DEGUELIN; FK506 BINDING PROTEIN 51; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; TOBACCO SMOKE; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; COMBINATION CHEMOTHERAPY; DNA ADDUCT; ENVIRONMENTAL EXPLOITATION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; ONCOGENE C MYC; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SMOKING;

EID: 84862303981     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/450179     Document Type: Review

References (138)

1. Yuan T. L., Cantley L. C., PI3K pathway alterations in cancer: variations on a theme Oncogene 2008 27 41 5497 5510
2. Engelman J. A., Luo J., Cantley L. C., The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nature Reviews Genetics 2006 7 8 606 619 (Pubitemid 44100518)
3. Engelman J. A., Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nature Reviews Cancer 2009 9 8 550 562
4. Argiris A., Karamouzis M. V., Raben D., Ferris R. L., Head and neck cancer The Lancet 2008 371 9625 1695 1709 (Pubitemid 351671886)
5. Leemans C. R., Braakhuis B. J., Brakenhoff R. H., The molecular biology of head and neck cancer Nature Reviews Cancer 2010 11 9 22
6. Molinolo A. A., Amornphimoltham P., Squarize C. H., Castilho R. M., Patel V., Gutkind J. S., Dysregulated molecular networks in head and neck carcinogenesis Oral Oncology 2009 45 4-5 324 334
7. Lu S. L., Reh D., Li A. G., Woods J., Corless C. L., Kulesz-Martin M., Wang X. J., Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation Cancer Research 2004 64 13 4405 4410 (Pubitemid 38856909)
8. Lu S. L., Herrington H., Reh D., Weber S., Bornstein S., Wang D., Li A. G., Tang C. F., Siddiqui Y., Nord J., Andersen P., Corless C. L., Wang X. J., Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma Genes and Development 2006 20 10 1331 1342 (Pubitemid 43727593)
9. Lu S. L., Herrington H., Wang X. J., Mouse models for human head and neck squamous cell carcinomas Head and Neck 2006 28 10 945 954 (Pubitemid 44497871)
10. Bornstein S., White R., Malkoski S., Oka M., Han G., Cleaver T., Reh D., Andersen P., Gross N., Olson S., Deng C., Lu S. L., Wang X. J., Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation Journal of Clinical Investigation 2009 119 11 3408 3419
11. Agrawal N., Frederick M. J., Pickering C. R., Bettegowda C., Chang K., Li R. J., Fakhry C., Xie T. X., Zhang J., Wang J., Zhang N., Elnaggar A. K., Jasser S. A., Weinstein J. N., Trevio L., Drummond J. A., Muzny D. M., Wu Y., Wood L. D., Hruban R. H., Westra W. H., Koch W. M., Califano J. A., Gibbs R. A., Sidransky D., Vogelstein B., Velculescu V. E., Papadopoulos N., Wheeler D. A., Kinzler K. W., Myers J. N., Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 Science 2011 333 6046 1154 1157
12. Stransky N., Egloff A. M., Tward A. D., Kostic A. D., Cibulskis K., Sivachenko A., Kryukov G. V., Lawrence M., Sougnez C., Mckenna A., Shefler E., Ramos A. H., Stojanov P., Carter S. L., Voet D., L cortés M., Auclair D., Berger M. F., Saksena G., Guiducci C., Onofrio R., Parkin M., Romkes M., Weissfeld J. L., Seethala R. R., Wang L., Rangel-Escareo C., Carlos fernandez-Lopez J., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S. B., Meyerson M., Lander E. S., Getz G., Golub T. R., Garraway L. A., Grandis J. R., The mutational landscape of head and neck squamous cell carcinoma Science 2011 333 6046 1154 1160
13. Zhao L., Vogt P. K., Class I PI3K in oncogenic cellular transformation Oncogene 2008 27 41 5486 5496
14. Guertin D. A., Sabatini D. M., Defining the role of mTOR in cancer Cancer Cell 2007 12 1 9 22 (Pubitemid 47001784)
15. Vasudevan K. M., Barbie D. A., Davies M. A., Rabinovsky R., McNear C. J., Kim J. J., Hennessy B. T., Tseng H., Pochanard P., Kim S. Y., Dunn I. F., Schinzel A. C., Sandy P., Hoersch S., Sheng Q., Gupta P. B., Boehm J. S., Reiling J. H., Silver S., Lu Y., Stemke-Hale K., Dutta B., Joy C., Sahin A. A., Gonzalez-Angulo A. M., Lluch A., Rameh L. E., Jacks T., Root D. E., Lander E. S., Mills G. B., Hahn W. C., Sellers W. R., Garraway L. A., AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer Cancer Cell 2009 16 1 21 32
16. Vogt P. K., Gymnopoulos M., Hart J. R., PI 3-kinase and cancer: changing accents Current Opinion in Genetics and Development 2009 19 1 12 17
17. Fan Q. W., Cheng C., Knight Z. A., Haas-Kogan D., Stokoe D., James C. D., McCormick F., Shokat K. M., Weiss W. A., EGFR signals to mTOR through PKC and independently of Akt in glioma Science Signaling 2009 2 55, article ra4
18. Lauring J., Cosgrove D. P., Fontana S., Gustin J. P., Konishi H., Abukhdeir A. M., Garay J. P., Mohseni M., Wang G. M., Higgins M. J., Gorkin D., Reis M., Vogelstein B., Polyak K., Cowherd M., Buckhaults P. J., Park B. H., Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations Oncogene 2010 29 16 2337 2345
19. Manning B. D., Cantley L. C., AKT/PKB signaling: navigating downstream Cell 2007 129 7 1261 1274 (Pubitemid 46962095)
20. Qiu W., Schonleben F., Li X., Ho D. J., Close L. G., Manolidis S., Bennett B. P., Su G. H., PIK3CA mutations in head and neck squamous cell carcinoma Clinical Cancer Research 2006 12 5 1441 1446
21. Qiu W., Tong G. X., Manolidis S., Close L. G., Assaad A. M., Su G. H., Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer International Journal of Cancer 2008 122 5 1189 1194 (Pubitemid 351214020)
22. Massion P. P., Taflan P. M., Shyr Y., Rahman S. M. J., Yildiz P., Shakthour B., Edgerton M. E., Ninan M., Andersen J. J., Gonzalez A. L., Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression American Journal of Respiratory and Critical Care Medicine 2004 170 10 1088 1094 (Pubitemid 39488621)
23. Pedrero J. M., Carracedo D., Pinto C. M. Jr., Herrero Zapatero A., Rodrigo J. P., Suarez Nieto C., Gonzalez M. V., Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma International Journal of Cancer 2005 114 2 242 248 (Pubitemid 40194293)
24. Estilo C. L., O-charoenrat P., Ngai I., Patel S. G., Reddy P. G., Dao S., Shaha A. R., Kraus D. H., Boyle J. O., Wong R. J., Pfister D. G., Huryn J. M., Zlotolow I. M., Shah J. P., Singh B., The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue Clinical Cancer Research 2003 9 6 2300 2306 (Pubitemid 36687656)
25. He Y., Van't Veer L. J., Mikolajewska-Hanclich I., van Velthuysen M. L. F., Zeestraten E. C. M., Nagtegaal I. D., van de Velde C. J. H., Marijnen C. A. M., PIK3CA mutations predict local recurrences in rectal cancer patients Clinical Cancer Research 2009 15 22 6956 6962
26. Saal L. H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J. S., Malmstrm P. O., Mansukhani M., Enoksson J., Hibshoosh H., Borg., Parsons R., PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Research 2005 65 7 2554 2559 (Pubitemid 40490050)
27. Akagi I., Miyashita M., Makino H., Nomura T., Hagiwara N., Takahashi K., Cho K., Mishima T., Ishibashi O., Ushijima T., Takizawa T., Tajiri T., Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma International Journal of Oncology 2009 34 3 767 775
28. Ogino S., Nosho K., Kirkner G. J., Shima K., Irahara N., Kure S., Chan A. T., Engelman J. A., Kraft P., Cantley L. C., Giovannucci E. L., Fuchs C. S., PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer Journal of Clinical Oncology 2009 27 9 1477 1484
29. Aleskandarany M. A., Rakha E. A., Ahmed M. A., Powe D. G., Paish E. C., MacMillan R. D., Ellis I. O., Green A. R., PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis Breast Cancer Research and Treatment 2010 122 1 45 53
30. Kozaki K. I., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H., Omura K., Inazawa J., PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma Cancer Science 2006 97 12 1351 1358 (Pubitemid 44614987)
31. Woenckhaus J., Steger K., Werner E., Fenic I., Gamerdinger U., Dreyer T., Stahl U., Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma Journal of Pathology 2002 198 3 335 342 (Pubitemid 35277384)
32. Fenic I., Steger K., Gruber C., Arens C., Woenckhaus J., Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma Oncology Reports 2007 18 1 253 259
33. Pang H., Flinn R., Patsialou A., Wyckoff J., Roussos E. T., Wu H., Pozzuto M., Goswami S., Condeelis J. S., Bresnick A. R., Segall J. E., Backer J. M., Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase Cancer Research 2009 69 23 8868 8876
34. Zhao J. J., Cheng H., Jia S., Wang L., Gjoerup O. V., Mikaini A., Roberts T. M., The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation Proceedings of the National Academy of Sciences of the United States of America 2006 103 44 16296 16300 (Pubitemid 44715190)
35. Gupta S., Ramjaun A. R., Haiko P., Wang Y., Warne P. H., Nicke B., Nye E., Stamp G., Alitalo K., Downward J., Binding of Ras to phosphoinositide 3-kinase p110alpha is required for Ras- driven tumorigenesis in mice Cell 2007 129 5 957 968 (Pubitemid 46802703)
36. Liang S., Yang N., Pan Y., Deng S., Lin X., Yang X., Katsaros D., Roby K. F., Hamilton T. C., Connolly D. C., Coukos G., Zhang L., Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation PLoS ONE 2009 4 1
37. Renner O., Blanco-Aparicio C., Grassow M., Canamero M., Leal J. F., Carnero A., Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation Cancer Research 2008 68 23 9643 9653
38. Engelman J. A., Chen L., Tan X., Crosby K., Guimaraes A. R., Upadhyay R., Maira M., McNamara K., Perera S. A., Song Y., Chirieac L. R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R. F., Garca-Echeverra C., Weissleder R., Mahmood U., Cantley L. C., Wong K. K., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nature Medicine 2008 14 12 1351 1356
39. Meyer D. S., Brinkhaus H., Muller U., Muller M., Cardiff R. D., Bentires-Alj M., Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors Cancer Research 2011 71 13 4344 4351
40. Liu P., Cheng H., Santiago S., Raeder M., Zhang F., Isabella A., Yang J., Semaan D. J., Chen C., Fox E. A., Gray N. S., Monahan J., Schlegel R., Beroukhim R., Mills G. B., Zhao J. J., Oncogenic PIK3CA -driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms Nature Medicine 2011 17 1116 1120
41. Jaiswal B. S., Janakiraman V., Kljavin N. M., Chaudhuri S., Stern H. M., Wang W., Kan Z., Dbouk H. A., Peters B. A., Waring P., Dela Vega T., Kenski D. M., Bowman K. K., Lorenzo M., Li H., Wu J., Modrusan Z., Stinson J., Eby M., Yue P., Kaminker J. S., de Sauvage F. J., Backer J. M., Seshagiri S., Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation Cancer Cell 2009 16 6 463 474
42. Chagpar R. B., Links P. H., Pastor M. C., Furber L. A., Hawrysh A. D., Chamberlain M. D., Anderson D. H., Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase Proceedings of the National Academy of Sciences of the United States of America 2010 107 12 5471 5476
43. Taniguchi C. M., Winnay J., Kondo T., Bronson R. T., Guimaraes A. R., Alemn J. O., Luo J., Stephanopoulos G., Weissleder R., Cantley L. C., Kahn C. R., The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling Cancer Research 2010 70 13 5305 5315
44. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B., The emerging mechanisms of isoform-specific PI3K signalling Nature Reviews Molecular Cell Biology 2010 11 5 329 341
45. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S. H., Zhang J., Signoretti S., Loda M., Roberts T. M., Zhao J. J., Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis Nature 2008 454 7205 776 779
46. Lee S. H., Poulogiannis G., Pyne S., Jia S., Zou L., Signoretti S., Loda M., Cantley L. C., Roberts T. M., A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice Proceedings of the National Academy of Sciences of the United States of America 2010 107 24 11002 11007
47. Ciraolo E., Iezzi M., Marone R., Marengo S., Curcio C., Costa C., Azzolino O., Gonella C., Rubinetto C., Wu H., Dastr W., Martin E. L., Silengo L., Altruda F., Turco E., Lanzetti L., Musiani P., Rckle T., Rommel C., Backer J. M., Forni G., Wymann M. P., Hirsch E., Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development Science Signaling 2008 1 36, article ra3
48. Keniry M., Parsons R., The role of PTEN signaling perturbations in cancer and in targeted therapy Oncogene 2008 27 41 5477 5485
49. Lee J. I., Soria J. C., Hassan K. A., El-Naggar A. K., Tang X., Liu D. D., Hong W. K., Mao L., Loss of PTEN expression as a prognostic marker for tongue cancer Archives of Otolaryngology 2001 127 12 1441 1445 (Pubitemid 33150608)
50. Poetsch M., Lorenz G., Kleist B., Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10 Cancer Genetics and Cytogenetics 2002 132 1 20 24 (Pubitemid 34136045)
51. Mirmohammadsadegh A., Marini A., Nambiar S., Hassan M., Tannapfel A., Ruzicka T., Hengge U. R., Epigenetic silencing of the PTEN gene in melanoma Cancer Research 2006 66 13 6546 6552 (Pubitemid 44085609)
52. Soria J. C., Lee H. Y., Lee J. I., Wang L., Issa J. P., Kemp B. L., Liu D. D., Kurie J. M., Mao L., Khuri F. R., Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation Clinical Cancer Research 2002 8 5 1178 1184 (Pubitemid 34517656)
53. Huang K. H., Huang S. F., Chen I. H., Liao C. T., Wang H. M., Hsieh L. L., Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma Clinical Cancer Research 2009 15 12 4174 4180
54. Squarize C. H., Castilho R. M., Pinto D. S. Jr., Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system Journal of Oral Pathology and Medicine 2002 31 7 379 384 (Pubitemid 34973684)
55. Cheung L. W., Hennessy B. T., Li J., Yu S., Myers A. P., Djordjevic B., Lu Y., Stemke-Hale K., Zhang F., Ju Z., High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability Cancer Discovery 2011 1 170 185
56. Darido C., Georgy S. R., Wilanowski T., Dworkin S., Auden A., Zhao Q., Rank G., Srivastava S., Finlay M. J., Papenfuss A. T., Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis Cancer Cell 2011 20 635 648
57. Kim H., Huang W., Jiang X., Pennicooke B., Park P. J., Johnson M. D., Integrative genome analysis reveals an oncomir/ oncogene cluster regulating glioblastoma survivorship Proceedings of the National Academy of Sciences of the United States of America 2010 107 5 2183 2188
58. Poliseno L., Salmena L., Riccardi L., Fornari A., Song M. S., Hobbs R. M., Sportoletti P., Varmeh S., Egia A., Fedele G., Rameh L., Loda M., Pandolfi P. P., Identification of the miR-106b 25 microRNA cluster as a proto-oncogenic PTEN -targeting intron that cooperates with its host gene MCM7 in transformation Science Signaling 2010 3 117, article ra29
59. Minor J., Wang X., Zhang F., Song J., Jimeno A., Wang X. J., Lu X., Gross N., Kulesz-Martin M., Wang D., Lu S. L., Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas Oral Oncology 2012 48 73 78
60. Wang X., Trotman L. C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P. P., Jiang X., NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN Cell 2007 128 1 129 139 (Pubitemid 46048884)
61. Fine B., Hodakoski C., Koujak S., Su T., Saal L. H., Maurer M., Hopkins B., Keniry M., Sulis M. L., Mense S., Hibshoosh H., Parsons R., Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a Science 2009 325 5945 1261 1265
62. Gewinner C., Wang Z. C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., Barretina J., Lin W. M., Rameh L., Salmena L., Pandolfi P. P., Cantley L. C., Evidence that inositol polyphosphate 4-phosphatase Type II is a tumor suppressor that inhibits PI3K signaling Cancer Cell 2009 16 2 115 125
63. Poliseno L., Salmena L., Zhang J., Carver B., Haveman W. J., Pandolfi P. P., A coding-independent function of gene and pseudogene mRNAs regulates tumour biology Nature 2010 465 7301 1033 1038
64. Vivanco I., Palaskas N., Tran C., Finn S. P., Getz G., Kennedy N. J., Jiao J., Rose J., Xie W., Loda M., Golub T., Mellinghoff I. K., Davis R. J., Wu H., Sawyers C. L., Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN Cancer Cell 2007 11 6 555 569 (Pubitemid 46856910)
65. Mounir Z., Krishnamoorthy J. L., Robertson G. P., Scheuner D., Kaufman R. J., Georgescu M. M., Koromilas A. E., Tumor Suppression by PTENR equires the activation of the PKR-eIF2alpha phosphorylation pathway Science Signaling 2009 2 102, article ra85
66. Hollander M. C., Blumenthal G. M., Dennis P. A., PTEN loss in the continuum of common cancers, rare syndromes and mouse models Nature Reviews Cancer 2011 11 4 289 301
67. Hollander M. C., Balogh A. R., Liwanag J., Han W., Linnoila R. I., Anver M. R., Dennis P. A., Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice Neoplasia 2008 10 8 866 872
68. Hill R., Calvopina J. H., Kim C., Wang Y., Dawson D. W., Donahue T. R., Dry S., Wu H., PTEN loss accelerates KrasG12D-induced pancreatic cancer development Cancer Research 2010 70 18 7114 7124
69. Puzio-Kuter A. M., Castillo-Martin M., Kinkade C. W., Wang X., Shen T. H., Matos T., Shen M. M., Cordon-Cardo C., Abate-Shen C., Inactivation of p53 and Pten promotes invasive bladder cancer Genes and Development 2009 23 6 675 680
70. Altomare D. A., Testa J. R., Perturbations of the AKT signaling pathway in human cancer Oncogene 2005 24 50 7455 7464 (Pubitemid 41637985)
71. Dutt A., Salvesen H. B., Greulich H., Sellers W. R., Beroukhim R., Meyerson M., Somatic mutations are present in all members of the AKT family in endometrial carcinoma British Journal of Cancer 2009 101 1218 1219
72. Carpten J. D., Faber A. L., Horn C., Donoho G. P., Briggs S. L., Robbins C. M., Hostetter G., Boguslawski S., Moses T. Y., Savage S., Uhlik M., Lin A., Du J., Qian Y. W., Zeckner D. J., Tucker-Kellogg G., Touchman J., Patel K., Mousses S., Bittner M., Schevitz R., Lai M. H. T., Blanchard K. L., Thomas J. E., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 2007 448 7152 439 444 (Pubitemid 47123510)
73. Bleeker F. E., Felicioni L., Buttitta F., Lamba S., Cardone L., Rodolfo M., Scarpa A., Leenstra S., Frattini M., Barbareschi M., Grammastro M. D., Sciarrotta M. G., Zanon C., Marchetti A., Bardelli A., AKT1E17K in human solid tumours Oncogene 2008 27 42 5648 5650
74. Eom H. S., Kim M. S., Hur S. Y., Yoo N. J., Lee S. H., Absence of oncogenic AKT1E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas Acta Oncologica 2009 48 7 1084 1085
75. Malanga D., Scrima M., De Marco C., Fabiani F., De Rosa N., De Gisi S., Malara N., Savino R., Rocco G., Chiappetta G., Franco R., Tirino V., Pirozzi G., Viglietto G., Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung Cell Cycle 2008 7 5 665 669 (Pubitemid 351499006)
76. Davies M. A., Stemke-Hale K., Tellez C., Calderone T. L., Deng W., Prieto V. G., Lazar A. J. F., Gershenwald J. E., Mills G. B., A novel AKT3 mutation in melanoma tumours and cell lines British Journal of Cancer 2008 99 8 1265 1268
77. Bellacosa A., Testa J. R., Moore R., Larue L., A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities Cancer Biology and Therapy 2004 3 3 268 275 (Pubitemid 41350878)
78. Cheng G. Z., Chan J., Wang Q., Zhang W., Sun C. D., Wang L. H., Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel Cancer Research 2007 67 5 1979 1987 (Pubitemid 46424214)
79. Rychahou P. G., Kang J., Gulhati P., Doan H. Q., Chen L. A., Xiao S. Y., Chung D. H., Evers B. M., Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis Proceedings of the National Academy of Sciences of the United States of America 2008 105 51 20315 20320
80. Stahl J. M., Sharma A., Cheung M., Zimmerman M., Cheng J. Q., Bosenberg M. W., Kester M., Sandirasegarane L., Robertson G. P., Deregulated Akt3 activity promotes development of malignant melanoma Cancer Research 2004 64 19 7002 7010 (Pubitemid 39331010)
81. Iamaroon A., Krisanaprakornkit S., Overexpression and activation of Akt2 protein in oral squamous cell carcinoma Oral Oncology 2009 45 10 e175 e179
82. Tsurutani J., Fukuoka J., Tsurutani H., Shih J. H., Hewitt S. M., Travis W. D., Jen J., Dennis P. A., Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors Journal of Clinical Oncology 2006 24 2 306 314 (Pubitemid 46622059)
83. Yang S. X., Costantino J. P., Kim C., Mamounas E. P., Nguyen D., Jeong J. H., Wolmark N., Kidwell K., Paik S., Swain S. M., Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer Journal of Clinical Oncology 2010 28 18 2974 2981
84. Amornphimoltham P., Sriuranpong V., Patel V., Benavides F., Conti C. J., Sauk J., Sausville E. A., Molinolo A. A., Gutkind J. S., Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01 Clinical Cancer Research 2004 10 12 4029 4037 (Pubitemid 38812478)
85. Molinolo A. A., Hewitt S. M., Amornphimoltham P., Keelawat S., Rangdaeng S., Garca A. M., Raimondi A. R., Jufe R., Itoiz M., Gao Y., Saranath D., Kaleebi G. S., Yoo G. H., Leak L., Myers E. M., Shintani S., Wong D., Massey H. D., Yeudall W. A., Lonardo F., Ensley J., Gutkind J. S., Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative Clinical Cancer Research 2007 13 17 4964 4973 (Pubitemid 47502060)
86. Massarelli E., Liu D. D., Lee J. J., El-Naggar A. K., Muzio L. L., Staibano S., De Placido S., Myers J. N., Papadimitrakopoulou V. A., Akt activation correlates with adverse outcome in tongue cancer Cancer 2005 104 11 2430 2436 (Pubitemid 41691564)
87. Yu Z., Weinberger P. M., Sasaki C., Egleston B. L., Speier W. F., Haffty B., Kowalski D., Camp R., Rimm D., Vairaktaris E., Burtness B., Psyrri A., Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer Cancer Epidemiology Biomarkers and Prevention 2007 16 3 553 558 (Pubitemid 46548660)
88. Irie H. Y., Pearline R. V., Grueneberg D., Hsia M., Ravichandran P., Kothari N., Natesan S., Brugge J. S., Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition Journal of Cell Biology 2005 171 6 1023 1034 (Pubitemid 41815834)
89. Yoeli-Lerner M., Yiu G. K., Rabinovitz I., Erhardt P., Jauliac S., Toker A., Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT Molecular Cell 2005 20 4 539 550 (Pubitemid 41668639)
90. Dillon R. L., Muller W. J., Distinct biological roles for the akt family in mammary tumor progression Cancer Research 2010 70 11 4260 4264
91. Hutchinson J. N., Jin J., Cardiff R. D., Woodgett J. R., Muller W. J., Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion Cancer Research 2004 64 9 3171 3178 (Pubitemid 38581419)
92. Dillon R. L., Marcotte R., Hennessy B. T., Woodgett J. R., Mills G. B., Muller W. J., Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression Cancer Research 2009 69 12 5057 5064
93. Iliopoulos D., Polytarchou C., Hatziapostolou M., Kottakis F., Maroulakou I. G., Struhl K., Tsichlis P. N., MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells Science Signaling 2009 2 92, article ra62
94. West K. A., Brognard J., Clark A. S., Linnoila I. R., Yang X., Swain S. M., Harris C., Belinsky S., Dennis P. A., Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells Journal of Clinical Investigation 2003 111 1 81 90 (Pubitemid 36134851)
95. Weber S. M., Bornstein S., Li Y., Malkoski S. P., Wang D., Rustgi A. K., Kulesz-Martin M. F., Wang X. J., Lu S. L., Tobacco-specific carcinogen nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces AKT activation in head and neck epithelia International Journal of Oncology 2011 39 1193 1198
96. Segrelles C., Lu J., Hammann B., Santos M., Moral M., Cascallana J. L., Lara M. F., Rho O., Carbajal S., Traag J., Beltrn L., Martnez-Cruz A. B., Garca-Escudero R., Lorz C., Ruiz S., Bravo A., Paramio J. M., DiGiovanni J., Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis Cancer Research 2007 67 22 10879 10888 (Pubitemid 350145917)
97. Moral M., Segrelles C., Lara M. F., Martnez-Cruz A. B., Lorz C., Santos M., Garca-Escudero R., Lu J., Kiguchi K., Buitrago A., Costa C., Saiz C., Rodriguez-Peralto J. L., Martinez-Tello F. J., Rodriguez-Pinilla M., Sanchez-Cespedes M., Garn M., Grande T., Bravo A., DiGiovanni J., Paramio J. M., Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma Cancer Research 2009 69 3 1099 1108
98. Brognard J., Sierecki E., Gao T., Newton A. C., PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms Molecular Cell 2007 25 6 917 931 (Pubitemid 46436532)
99. Liu J., Weiss H. L., Rychahou P., Jackson L. N., Evers B. M., Gao T., Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis Oncogene 2009 28 7 994 1004
100. Chen M., Pratt C. P., Zeeman M. E., Schultz N., Taylor B. S., O'Neill A., Castillo-Martin M., Nowak D. G., Naguib A., Grace D. M., Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression Cancer Cell 2011 20 173 186
101. Pei H., Li L., Fridley B. L., Jenkins G. D., Kalari K. R., Lingle W., Petersen G., Lou Z., Wang L., FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt Cancer Cell 2009 16 3 259 266
102. Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A. J., Hirata N., Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S., Obata T., Noguchi M., The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt Developmental Cell 2009 17 6 800 810
103. Kawase T., Ohki R., Shibata T., Tsutsumi S., Kamimura N., Inazawa J., Ohta T., Ichikawa H., Aburatani H., Tashiro F., Taya Y., PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt Cell 2009 136 3 535 550
104. Maurer M., Su T., Saal L. H., Koujak S., Hopkins B. D., Barkley C. R., Wu J., Nandula S., Dutta B., Xie Y., Chin Y. R., Kim D. I., Ferris J. S., Gruvberger-Saal S. K., Laakso M., Wang X., Memeo L., Rojtman A., Matos T., Yu J. S., Cordon-Cardo C., Isola J., Terry M. B., Toker A., Mills G. B., Zhao J. J., Murty V. V. V. S., Hibshoosh H., Parsons R., 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma Cancer Research 2009 69 15 6299 6306
105. Xie Z., Yuan H., Yin Y., Zeng X., Bai R., Glazer R. I., 3-Phosphoinositide-dependent Protein Kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases BMC Cancer 2006 6, article 77
106. Liu Y., Wang J., Wu M., Wan W., Sun R., Yang D., Sun X., Ma D., Ying G., Zhang N., Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells Molecular Cancer Research 2009 7 6 944 954
107. Bayascas J. R., Leslie N. R., Parsons R., Fleming S., Alessi D. R., Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN +/- mice Current Biology 2005 15 20 1839 1846 (Pubitemid 41501519)
108. Yu Y., Yoon S. O., Poulogiannis G., Yang Q., Ma X. M., Villén J., Kubica N., Hoffman G. R., Cantley L. C., Gygi S. P., Blenis J., Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling Science 2011 332 6035 1322 1326
109. Zoncu R., Efeyan A., Sabatini D. M., MTOR: from growth signal integration to cancer, diabetes and ageing Nature Reviews Molecular Cell Biology 2011 12 1 21 35
110. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N. G., Sauk J. J., Sausville E. A., Molinolo A. A., Gutkind J. S., Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck Cancer Research 2005 65 21 9953 9961 (Pubitemid 41541476)
111. Morris L. G., Taylor B. S., Bivona T. G., Gong Y., Eng S., Brennan C. W., Kaufman A., Kastenhuber E. R., Banuchi V. E., Singh B., Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers Proceedings of the National Academy of Sciences of the United States 2011 108 19024 19029
112. Chakraborty S., Mohiyuddin S. M., Gopinath K. S., Kumar A., Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma BMC Cancer 2008 8, article 163
113. Kawaguchi S., Harada K., Supriatno, Yoshida H., Sato M., Overexpression of tuberous sclerosis complex 2 exerts antitumor effect on oral cancer cell lines Oral Oncology 2003 39 8 836 841 (Pubitemid 38373468)
114. Qiu W., Schonleben F., Thaker H. M., Goggins M., Su G. H., A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma Oncogene 2006 25 20 2937 2942 (Pubitemid 43739244)
115. Kline E. R., Muller S., Pan L., Tighiouart M., Chen Z. G., Marcus A. I., Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastasis Head Neck 2011 33 1501 1512
116. Czerninski R., Amornphimoltham P., Patel V., Molinolo A. A., Gutkind J. S., Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model Cancer Prevention Research 2009 2 1 27 36
117. Raimondi A. R., Molinolo A., Gutkind J. S., Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model Cancer Research 2009 69 10 4159 4166
118. Nathan C. O., Amirghahari N., Rong X., Giordano T., Sibley D., Nordberg M., Glass J., Agarwal A., Caldito G., Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer Cancer Research 2007 67 5 2160 2168 (Pubitemid 46424235)
119. West K. A., Linnoila I. R., Belinsky S. A., Harris C. C., Dennis P. A., Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′; -Kinase/Akt pathway in vitro and in vivo Cancer
120. Vitale-Cross L., Czerninski R., Amornphimoltham P., Patel V., Molinolo A. A., Gutkind J. S., Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer Cancer Prevention Research 2009 2 5 419 422
121. Lee H. Y., Oh S. H., Woo J. K., Kim W. Y., Van Pelt C. S., Price R. E., Cody D., Tran H., Pezzuto J. M., Moriarty R. M., Hong W. K., Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis Journal of the National Cancer Institute 2005 97 22 1695 1699 (Pubitemid 41672236)
122. Memmott R. M., Mercado J. R., Maier C. R., Kawabata S., Fox S. D., Dennis P. A., Metformin prevents tobacco carcinogeninduced lung tumorigenesis Cancer Prevention Research 2009 3 1066 1076
123. Athar M., Back J. H., Kopelovich L., Bickers D. R., Kim A. L., Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms Archives of Biochemistry and Biophysics 2009 486 95 102
124. Frojdo S., Cozzone D., Vidal H., Pirola L., Resveratrol is a class IA phosphoinositide 3-kinase inhibitor Biochemical Journal 2007 406 3 511 518 (Pubitemid 47425457)
125. McDermott U., Settleman J., Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology Journal of Clinical Oncology 2009 27 33 5650 5659
126. Liu P., Cheng H., Roberts T. M., Zhao J. J., Targeting the phosphoinositide 3-kinase pathway in cancer Nature Reviews Drug Discovery 2009 8 8 627 644
127. Freudlsperger C., Burnett J. R., Friedman J. A., Kannabiran V. R., Chen Z., Van Waes C., EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy Expert Opinion on Therapeutic Targets 2011 15 1 63 74
128. O'Brien C., Wallin J. J., Sampath D., GuhaThakurta D., Savage H., Punnoose E. A., Guan J., Berry L., Prior W. W., Amler L. C., Belvin M., Friedman L. S., Lackner M. R., Predictive biomarkers of sensitivity to the phosphatidylinositol 3′; kinase inhibitor GDC-0941 in breast cancer preclinical models Clinical Cancer Research 2010 16 14 3670 3683
129. Wallin J. J., Guan J., Prior W. W., Edgar K. A., Kassees R., Sampath D., Belvin M., Friedman L. S., Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer Science Translational Medicine 2010 2 48
130. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., Russo M., Cancelliere C., Zecchin D., Mazzucchelli L., Sasazuki T., Shirasawa S., Geuna M., Frattini M., Baselga J., Gallicchio M., Biffo S., Bardelli A., Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus Journal of Clinical Investigation 2010 120 8 2858 2866
131. Andersen J. N., Sathyanarayanan S., Di Bacco A., Chi A., Zhang T., Chen A. H., Dolinski B., Kraus M., Roberts B., Arthur W., Klinghoffer R. A., Gargano D., Li X., Feldman I., Lynch B., Rush J., Hendrickson R. C., Blume-Jensen P., Paweletz C. P., Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors Science Translational Medicine 2010 2 43
132. Bernier J., Bentzen S. M., Vermorken J. B., Molecular therapy in head and neck oncology Nature Reviews Clinical Oncology 2009 6 5 266 277
133. Brand T. M., Iida M., Wheeler D. L., Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab Cancer Biology and Therapy 2011 11 9 777 792
134. Tanaka K., Babic I., Nathanson D., Akhavan D., Guo D., Gini B., Dang J., Zhu S., Yang H., de Jesus J., Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance Cancer Discovery 2011 1 524 538
135. Bussink J., van der Kogel A. J., Kaanders J. H., Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer The Lancet Oncology 2008 9 3 288 296 (Pubitemid 351722948)
136. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P. K., Baselga J., Rosen N., AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity Cancer Cell 2011 19 1 58 71
137. Rodrik-Outmezguine V. S., Chandarlapaty S., Pagano N. C., Poulikakos P. I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N., MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling CancerDiscovery 2011 1 248 259
138. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A. T., Thomas G., Kozma S. C., Papa A., Nardella C., Cantley L. C., Baselga J., Pandolfi P. P., Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer Journal of Clinical Investigation 2008 118 9 3065 3074